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Abstract
Background: Serial interferon-gamma-release-assay (IGRA) result can show variance due to within-subject variation
and difference in host immune status, and may be affected by latent tuberculosis infection (LTBI) treatment. We aimed
to know the changes in QFT-IT (QuantiFERON-TB Gold In-Tube) results measured at a 4 month interval in end stage renal
disease patients and whether these changes were influenced by dialysis method or LTBI treatment.
Methods: We prospectively performed serial QFT-IT tests at 4 month interval in 93 end stage renal disease (ESRD)
patients on HD (hemodialysis) or PD (peritoneal dialysis). LTBI treatment was given to 18 of 39 patients with initial positive
QFT-IT result. Agreement between the two results was estimated for all 93 patients and reversion rates were estimated
among the 39 patients with initial positive QFT-IT.
Results: Positive QFT-IT at the first and 2nd tests were 41.9 and 34.4 %, respectively. The concordance rate between
baseline QFT-IT and 2nd QFT in 93 ESRD patients was excellent (90.3 %, kappa = 0.80, p < 0.001). Agreement between the
first QFT-IT and 2nd QFT-IT in HD (95.3 %, kappa = 0.91, p < 0.001) was higher than in PD patients (86.0 %, kappa = 0.69,
p < 0.001). Among all ESRD patients, the odds of reversion of QFT-IT was not different in those who were, or were not
treated for LTBI [odds ratio = 2.3 (0.5–11.4), p = 0.43].
Conclusions: In a group of 93 dialyzed ESRD patients 8.6 % showed reversion of initial positive QFT to negative within
4 months. Reversion seemed not to be associated with LTBI treatment. Further study with larger numbers of patients is
needed to investigate the variation of QFT-IT tests in dialyzed ESRD patients.
Keywords: Interferon-gamma release assay, Latent tuberculosis, End stage renal disease, Dialysis, Reversion
Background
Tuberculosis (TB) remains an important global health
issue, and is the single most significant infectious cause of
morbidity and mortality in the world, with approximately
2 million deaths and around 9 million new cases each year
[1–3]. LTBI diagnosis and treatment is a part of the strat-
egy for TB elimination in countries with low or intermedi-
ate burden [4, 5].
There are several clinical conditions in which the risk
for active TB is increased. ESRD patients as well as
renal-transplant patients on immune suppressive agents
who have LTBI have an increased risk for progressive
active TB [6]. The annual incidence of active TB in
South Korea where BCG vaccination is mandatory is
intermediate (84/100,000) [7] and that of active TB in
renal transplant patients is 0.5 %/year in South Korea
[8]. Therefore, it would be better to treat LTBI in dia-
lyzed ESRD patients before transplantation, because
prophylactic TB drug like rifampicin can lead to drug
interaction with immune suppression drug on kidney-
transplantation recipients [9].
End stage renal disease (ESRD) is known to compromise
cellular immune function, and patients on dialysis have
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been shown to have T cell dysfunction including abnormal
IFN-gamma levels, considered to have a pivotal role in
controlling latent TB infection [10, 11]. A high per-
centage of the ESRD patients show no skin reaction to
tuberculin skin test (TST) as they are anergic [12, 13].
Interferon-gamma release assays (IGRAs) are useful
tools for diagnosing LTBI, because they are more spe-
cific, particularly in BCG vaccinated populations [14],
and may identify some additional patients with latent
TB among kidney-transplantation (KT) recipients with
a negative TST [15].
Therefore, IGRA may be useful in this patient popu-
lation to detect TB infection, but the use of serial
IGRA testing to detect new TB infection in these pa-
tients is controversial because of non-specific vari-
ation, conversions, and reversions. Lee et al. reported
that QFT-IT test reversion occurred in 41.9 % of the
subjects and IFN-gamma levels decreased in almost all
subjects after LTBI treatment [16].
Although previous studies have proposed that con-
versions, reversions, and non-specific variations can
occur with serial IGRA testing [17, 18], there are no
studies about serial changes of IGRAs in patients
with end stage renal disease who receive LTBI treat-
ment. We prospectively evaluated QFT-IT tests on
two occasions at a four month interval in dialyzed
ESRD patients, some of whom received LTBI treat-
ment, to estimate the variation of the QFT-IT on re-




ESRD patients on Peritoneal dialysis (PD) or hemo-dialysis
(HD) were enrolled in this study. QFT-IT test was per-
formed initially for screening of LTBI, and the patients with
positive QFT-IT started to receive 9 months of isoniazid
treatment or 4 months of rifampicin treatment immedi-
ately. The QFT-IT test was repeated at 4 months interval
for all the subjects including a sub-group who received
Isoniazid for 9 months or rifampicin for 4 months- all of
whom took > 80 % of doses. Chest radiographs were
screened before LTBI treatment. Written informed consent
was obtained from study participants, and the study was
approved by the Institutional Review Board of the Inje
University Busan Paik hospital.
QuantiFERON-TB Gold In-Tube test
All participants were tested with the QFT-IT test per the
manufacturer’s instructions. An IFN-gamma response to
the ESAT-6/CFP-10/TB7.7 mixture ≥0.35 IU/mL above the
nil control value (and ≥25 % of the nil control) was consid-
ered a positive result for the QFT-IT test. QFT-IT test re-
version was defined as a change from a positive (≥0.35 IU/
mL) to a negative (<0.35 IU/mL) result, and conversion as
a change from a negative (<0.35 IU/mL) to a positive
(≥0.35 IU/mL) result.
Statistical analysis
All analyses were performed using SPSS software, version
12.0 (SPSS Inc., Chicago, IL, USA). Between-group
Table 1 Clinical characteristics of the study population
Clinical characteristics Total (n = 93) HD (n = 43) PD (n = 50) P-value
Mean age, years (range) 51.6 (23–74) 52.8 (31–74) 50.6 (23–72) 0.41
Gender (Male : Female) 43:50 19:24 24:26 0.71
BMI, kg/m2, mean ± SD 23.0 ± 3.7 22.6 ± 3.1 23.3 ± 4.3 0.44
Cause for ESRD
DM 34 (36.6) 19 (44.2) 15 (30.0) 0.23
HTN 44 (47.3) 19 (44.2) 25 (50.0) 0.73
aOthers 15 (16.1) 5 (11.6) 10 (20.0) 0.66
Use of steroid 2 (2.2) 1 (2.3) 1 (2) 1.0
Previous TB treatment (%) 0 (0) 0 (0) 0 (0) 1.0
Presence of BCG scar (%) 62/93 (66.7) 19/43 (44.2) 43/50 (86.0) 0.001
Baseline QFT-IT + (%) 39/93 (41.9) 19/43 (44.2) 20/50 (40.0) 0.68
2nd QFT-IT + (%) 32/93 (34.4) b19/43 (44.2) 13/50 (26.0) 0.07
Old TB lesion (%) 35/93 (37.6) 14/43 (32.6) 21/50 (42.0) 0.35
LTBI treatment among initial QFT-IT + (%) 18/39 (46.2) 5/19 (26.3) 13/20 (65.0) 0.02
Isoniazid: Rifampicin 10:8 3:2 7:6 1.0
aOthers include autoimmune diseases, glomerulonephritis, polycystic kidney diseases, and unknown diseases
bOne of 19 patients showed conversion from negative to positive result
HD Hemo-dialysis, PD peritoneal dialysis, BMI body mass index, TB tuberculosis, LTBI latent TB infection, BCG bacille Calmette-Guérin, QFT-IT QuantiFERON-TB Gold
In-Tube, SD standard deviation
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comparisons were made with t-test and Mann–Whitney
test for variables. Concordance between test results from
first QFT-IT and 2nd QFT-IT test was assessed using kappa
coefficients. The χ2 tests was used to test for difference
between reversion group and non-reversion group, and
paired changes of interferon-gamma levels was ana-
lyzed by Wilcoxon signed rank test. All tests for signifi-
cance were two-sided and statistical significance was
established at P values < 0.05.
Results
Demographics of the participants
A total of 150 ESRD patients were screened with QFT-IT
and chest radiographs. The QFT-IT test was repeated for
the initially screened patients, but both baseline QFT-IT
and 2nd QFT-IT test results were available for 93 patients
finally (Table 1). In other words, 2nd QFT-IT test could not
be performed for 57 ESRD patients (HD:22, PD:35),
because 6 patients (HD:2, PD:4) were in inpatient care for
associated disease, 13 patients (HD:6, PD:7) were trans-
ferred out to other hospital, and 38 patients (HD:14, PD:24)
refused to participate in further study. Old TB lesion on
chest radiograph was found on 35 (37.6 %) patients among
them. Hemodialysis was used for 43 ESRD patients, and
peritoneal dialysis was used for 50 ESRD patients. The
mean age was 51.6 years (range, 23–74 years) and the
male-to-female ratio was 43:50. A BCG scar was present in
62 patients (66.7 %). The positive rates of the 1st QFT-IT at
baseline testing and 2nd QFT-GIT testing at the 4 month
follow-up were 41.9 and 34.4 %, respectively. Isoniazid was
prescribed for 10 patients and rifampicin was prescribed for
8 patients for the treatment of patients with LTBI showing
positive QFT-IT results. There were no differences between
the HD group and PD group in age, gender, BMI, positive
rate of QFT-IT except the presence of BCG scar and the
rate of LTBI treatment (Table 1).
Changes in QFT-IT result in ESRD patients between 0 and
4 months
The agreement between baseline QFT-IT and 2nd QFT at
4 month interval in 93 ESRD patients was excellent
(90.3 %, kappa = 0.80, p < 0.001) (Table 2). Agreement
between baseline QFT-IT and 2nd QFT-IT in HD (95.3 %,
kappa = 0.91, p <0.001) was higher than in PD patients
(86.0 %, kappa = 0.69, p < 0.001).
Changes in QFT-IT among ESRD patients with 1st QFT-
positive results
Among 39 patients who showed positive QFT-IT result
at first testing, QFT-IT test reversion occurred in 8
(20.5 %) patients, of whom seven (87.5 %) were on PD,
and one patient (12.5 %) was on HD [odds ratio = 9.7
(1.1–88.7), p = 0.04] (Table 3). However, conversion rate
was not different between them (0 vs. 2.3 %, p > 0.05). The
median actual interferon-gamma levels of QFT-IT in HD
group and PD group at baseline were; 1.55 (IQR 0.7–3.7)
Table 2 1st QFT-IT and 2nd QFT-IT test results in 93 ESRD patients
Dialysis 1st QFT-IT positive (n = 39a) 1st QFT-IT negative (n = 54a) Total Kappa P value
2nd QFT-IT positive 2nd QFT-IT negative 2nd QFT-IT positive 2nd QFT-IT negative (N) (%)
HD 18/43 (41.9 %) 1/43 (2.3 %) 1/43 (2.3 %) 23/43 (53.5 %) 43 0.91 (95.3 %) <0.001*
PD 13/50 (26.0 %) 7/50 (14.0 %) 0/50 (0 %) 30/50 (60.0 %) 50 0.69 (86.0 %) <0.001*
Total 31/93 (33.3 %) 8/93 (8.6 %) 1/93 (1.1 %) 53/93 (57.0 %) 93 0.80 (90.3 %) <0.001*
aAmong 93 ESRD patients, 39 patients showed QFT-IT positive results and 54 patients showed QFT-IT negative results on baseline QFT-IT tests, respectively
*Difference for concordance between 1st QFT-IT and 2nd QFT-IT
QFT-IT QuantiFERON-TB Gold In-Tube, PD peritoneal dialysis, HD hemodialysis
Table 3 Reversion and non-reversion of QFT-IT among ESRD patients with 1st QFT-IT positive result
ESRD patients (N = 39) Reversion Non-reversion OR (95 % CI) P value
Dialysis method
PD 7 (35.0 %) 13 (65.0 %) 9.7 (1.1–88.7) 0.04
HD 1 (5.3 %) 18 (94.7 %) 1 (Ref.)
Treatment
LTBI treatment 5 (27.8 %) 13 (72.2 %) 2.3 (0.5–11.4) 0.43
No LTBI Treatment 3 (14.3 %) 18 (85.7 %) 1 (Ref.)
Treatment drug
Rifampin 3 (37.5 %) 5 (62.5 %) 2.4 (0.3–19.8) 0.61
INH 2 (20.0 %) 8 (80.0 %) 1 (Ref.)
OR odds ratio, PD peritoneal dialysis, HD hemodialysis, LTBI latent tuberculosis infection, RFP rifampicin, INH isoniazid
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and 5.03 (IQR 0.9–15.4) respectively. The median values
after 4 months were: HD= 0.87 (IQR 0.6–3.4), and PD =
1.31 (IQR 0.2–4.5). The change in median values of QFT-
IT between baseline and 4 months was significantly differ-
ent with HD= 8 % decrease, and PD= 76 % (p < 0.001)
Among the 39 with baseline positive IGRA tests, there
was no significant difference in the percent decline in
interferon-gamma levels of QFT-IT tests over 4 months
among the 18 who received LTBI treatment group and the
21 who were not treated (Decrease of 64 % among treated
vs. 43 % among untreated, p > 0.05). However, as seen in
Fig. 1, median values decreased significantly in both groups
over the 4 month interval. Reversion odds of the QFT-IT
test in the groups who received, or did not receive LTBI
treatment were not significant [odds of reversion = 2.3
(0.5–11.4)]. Furthermore, there were no difference in rever-
sion odds of the serial QFT-IT test between those treated
with RIF or INH [odds ratio = 2.4 (0.3–19.8)].
Fig. 1 Changes of interferon-gamma levels over 4 months in those with positive QFT-IT at baseline. Paired changes of interferon-gamma levels in
QFT-IT tests after 4 months in the LTBI treatment group (a) and in the LTBI no treatment group (b), as well as in the hemodialysis group (c) and
in the peritoneal dialysis group (d). The horizontal bold lines at pre- and post-treatment values represent the median interferon-gamma values
(a median 1.40 with IQR 0.8–12.0 and median 0.51 with IQR 0.3–3.4, b median 3.19 with IQR 0.8–10.1 and median 1.29 with IQR 0.7–3.7, c median
1.55 with IQR 0.7–3.7 and median 0.87 with IQR 0.6–3.4, d median 5.03 with IQR 0.9–15.4 and median 1.31 with IQR 0.2–4.5). QFT-IT:
QuantiFERON-TB Gold In-Tube; IQR: interquartile range
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Discussion
Within-subject variability of QFT-IT at 4 month interval in
dialyzed ESRD patients was minimal. Reversion of QFT-IT
after a 4 month interval was not related to LTBI treatment
but was more frequent in PD patients than in HD patients.
QFT-IT in our study was checked in ESRD patients; the
concordance rate in all ESRD patients was relatively high
(90.3 %, kappa = 0.80), compared with previous study in
which concordance rate at 1 year interval without LTBI
treatment in ESRD patients was 70.4 % with T-SPOT-TB
and 73.5 % with QFT-IT [19]. Furthermore, reversion
rates after LTBI treatment in our study were relatively low
(27.8 %, 5/18), compared with previous study in which
IGRA reversion rates were 41.9 % with 4 months of rifam-
picin treatment [16]. Also, in case of conversion, only
1.9 % (1/54) HD patient showed conversion of QFT-IT in
our study, which was relatively lower than 12.1 % in
patients who was taking the immune-suppressive drugs at
8.5 month interval [20] and 6 % in ordinary patients with
infectious disease at 3 month interval [21]. Compared
with these studies, our result for ESRD patients with
4 month follow up showed low variance of IFN-gamma
level. The reason why within-subject variability was low
seems to be due to immune dysfunction of ESRD patients
related to uremia and dialysis [11] as well as due to short
term interval of QFT-IT follow up.
In our study, there is possibility that the LTBI treat-
ment reduced the IFN-gamma level because 2nd IFN-
gamma level decreased from baseline level more fre-
quently in LTBI treatment group (17/18, 94.4 %) than in
LTBI no treatment group (14/21, 66.7 %) (p = 0.049).
However, the 2nd IFN-gamma level did not sufficiently
decrease to reach to the defined cut-off level 0.35 IU/
mL, and there were no difference in degree of decrease
between two group (median value of percent decrease,
64.0 VS. 42.8 %, p > 0.05). Therefore, the threshold for
IFN-gamma cut-off point must be considered to be re-
defined which is optimal for distinguishing true rever-
sion and non-specific variation.
The main reasons for the predominant reversion of
QFT-IT in PD patients compared with HD patients may
be the differences in immune activity and serum sam-
pling time as well as in LTBI treatment rate (65.0 VS.
26.3 %, P = 0.02) between PD patients and HD patients.
As seen in Fig. 1c and d, the median IFN-gamma levels
on two time point were higher in PD patents than in
HD patients, and the percent decrease in IFN-gamma
level from baseline QFT-IT to sequential 4 month QFT-
IT was significantly higher in PD patients than in HD
patients (median value of percent decrease, 75.5 VS.
8.0 %, p < 0.001). This result could be occurred by acci-
dent, but T-SPOT TB which was reported to be equiva-
lent to or inferior to QFT-IT in sensitivity [22] can be
tested for reproducibility in PD patients to quantify the
degree of decrease as another method. The explainable
hypothesis for the difference of immune activity between
HD and PD patients is that lymphopenia, decreased
absolute counts of lymphocyte, and decreased production
of interferon-gamma levels are more apparent in HD pa-
tients than in PD patients [23]. Circulating immune cells in
PD patients may be more easily exhausted by chronic
uremic activation [24]. Also, the timing in collecting the
blood sample for QFT-IT could influence the variation of
QFT-IT result of PD, because it was reported that the IFN-
gamma level of post-dialysis could be reduced compared
with that of pre-dialysis [25]. In our study, blood sampling
was performed equally before dialysis in HD patients, but
in PD patients, not equally before or after dialysis.
This study had some limitations. Firstly, the number
of participants was small and the tuberculin skin tests
were not performed in most of patients due to difficulty
in follow up schedule for interpretation of TST results.
Secondly, the timing for blood sampling in dialysis pa-
tients could not be equally conditioned for all subjects.
Lastly, because the follow up interval is short, the serial
extended follow up of QFT-IT at 9 months after LTBI
treatment for more than 4 months is needed for con-
firming the variation of within-subject variability.
Conclusions
The concordance rate of QFT-IT for 4 month interval in
dialyzed ESRD patients in a Korean population was ex-
cellent, and reversion seemed not to be associated with
LTBI treatment. Further studies with extended follow up
as well as with larger numbers of patients are needed to
investigate the changes of QFT-IT including the effect of
LTBI treatment in dialyzed ESRD patients.
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